Ontology highlight
ABSTRACT:
SUBMITTER: Schneider BK
PROVIDER: S-EPMC6709425 | biostudies-other | 2019 Aug
REPOSITORIES: biostudies-other
CPT: pharmacometrics & systems pharmacology 20190509 8
Bevacizumab-pemetrexed/cisplatin (BEV-PEM/CIS) is a first-line therapeutic for advanced nonsquamous non-small cell lung cancer. Bevacizumab potentiates PEM/CIS cytotoxicity by inducing transient tumor vasculature normalization. BEV-PEM/CIS has a narrow therapeutic window. Therefore, it is an attractive target for administration schedule optimization. The present study leverages our previous work on BEV-PEM/CIS pharmacodynamic modeling in non-small cell lung cancer-bearing mice to estimate the op ...[more]